Results 251 to 260 of about 3,067,072 (318)

JAK inhibitors alleviate EGFR-inhibitor-induced diarrhea by protecting intestinal stem cells from adaptive-immune-exacerbated injury. [PDF]

Nat Commun
Cheng Y, Xu C, Lv D, Tian M, Wang H, Yang B, Chen L, You Q, Zhang S.   +8 more
europepmc   +1 more source

Mycobacterial cell division arrest and smooth‐to‐rough envelope transition using CRISPRi‐mediated genetic repression systems

FEBS Open Bio, EarlyView.
CRISPRI‐mediated gene silencing and phenotypic exploration in nontuberculous mycobacteria. In this Research Protocol, we describe approaches to control, monitor, and quantitatively assess CRISPRI‐mediated gene silencing in M. smegmatis and M. abscessus model organisms.
Vanessa Point, Wafaa Achache, Janïs Laudouze, Eliana Sepulveda Ramos, Mickaël Maziero, Céline Crauste, Stéphane Canaan, Pierre Santucci   +7 more
wiley   +1 more source

Herpes Zoster in Patients Treated with JAK Inhibitors for Immune-Mediated Inflammatory Diseases: Incidence, Associated Factors and Vaccination Uptake in a Real-World Cohort. [PDF]

J Clin Med
Parchão A, Monteiro C, Araújo-Andrade L, Dias CC, Abreu C.   +4 more
europepmc   +1 more source

Nuclear pore links Fob1‐dependent rDNA damage relocation to lifespan control

FEBS Open Bio, EarlyView.
Damaged rDNA accumulates at a specific perinuclear interface that couples nucleolar escape with nuclear envelope association. Nuclear pores at this site help inhibit Fob1‐induced rDNA instability. This spatial organization of damage handling supports a functional link between nuclear architecture, rDNA stability, and replicative lifespan in yeast.
Yamato Okada, Mina Iwaki, Kyosuke Hagiri, Rei Izumi, Masahiko Harata, Chihiro Horigome   +5 more
wiley   +1 more source

Strategies for Managing Suboptimal Response to JAK Inhibitors in Alopecia Areata. [PDF]

Acta Derm Venereol
Seyed Jafari SM, De Viragh PA.
europepmc   +1 more source

JAK Inhibitors for Treatment of SAPHO Syndrome: A Systematic Review of 72 Cases. [PDF]

ACR Open Rheumatol
Fazeli P, Bahramian S, Farahmand K, Ghoshouni H, Farahmand Y, Soheili A, Bagheri L, Memari H, Feyzi A, Vahabi SM.   +9 more
europepmc   +1 more source

Topical Ruxolitinib and Delgocitinib Versus Systemic JAK Inhibitors: A Comparative Safety Review. [PDF]

Int J Mol Sci
Böll SL, Seyed Jafari SM, Conrad C, Schlapbach C.   +3 more
europepmc   +1 more source

Use of JAK Inhibitors in Lichen Planus: An Update. [PDF]

Medicina (Kaunas)
Didona D, Caposiena Caro RD, Calabrese L, D'Onghia M, Galluccio G, Di Nicola MR, Rallo A, Paolino G.   +7 more
europepmc   +1 more source

Clinical and Ultrasound Remission in Rheumatoid Arthritis Patients Treated with JAK Inhibitors: A Real-World Study. [PDF]

J Clin Med
Lasa-Teja C, Fernández-Cabero JJ, Sánchez-Bilbao L, Loricera J, González-Mazón I, Álvarez-Reguera C, Herrero-Morant A, Corrales-Martínez A, Portilla-González V, Martín-Varillas JL, Pérez-Garrido L, Santos-Gómez M, López-Hoyos M, Blanco R.   +13 more
europepmc   +1 more source